Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer Nov 22, 2021
Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing Folate-Receptor Alpha (FRĪ±) Sep 17, 2021
Elucida Oncology Submits IND Application for ELU-001 for the Treatment of Cancers Overexpressing Folate-Receptor Alpha Jul 19, 2021
Elucida Oncology Announces Three Key Additions to Its Board of Directors and the Appointment of Robert Essner as Chairman of the Board Apr 29, 2021
Elucida Oncology to Present Preclinical Data on ELU001 at the American Association for Cancer Research Annual Meeting Mar 29, 2021
Elucida Oncology Taps Geno J. Germano, Veteran Pfizer Executive and Former Intrexon President, as New CEO Aug 22, 2018
Nature Study Leverages Artificial Intelligence to Reveal Never-before-seen Cage Structure of Ultra-small Particles Jun 20, 2018
